Saturday, October 12, 2024 4:03:40 PM
Manibiotech, Here are the real lies:
1. DCVAX would never complete its trial. DCvax completed the trial with spectacular results.
2. Trial results will never be published in a reputable journal. TLD published by JAMA, discussed by NYAS, ASCO, SCO, etc
3. Production of 'personalized' dcvax would be too inefficient like dendreon/provenge. Automation, through Flaskwork, obtained.
4. NWBO would never be able to adequately protect DCVAX from BPs. NWBO's and ROSWELL's patents serve as a barrier of entry, preventing any BP from developing a competing dendritic-based treatment.
5. Wall-street would severely limit NWBO's ability to raise needed funding, resulting in preventing NWBO from crossing the finish line. NWBO not only got to the finish line, they may very well bankrupt money-makers and SHFs via the outcome of its lawsuit and open the floodgates for other companies to sue these bastards.
Despite all of this, you and others conclude NWBO management is incompetent. WHY?
1. DCVAX would never complete its trial. DCvax completed the trial with spectacular results.
2. Trial results will never be published in a reputable journal. TLD published by JAMA, discussed by NYAS, ASCO, SCO, etc
3. Production of 'personalized' dcvax would be too inefficient like dendreon/provenge. Automation, through Flaskwork, obtained.
4. NWBO would never be able to adequately protect DCVAX from BPs. NWBO's and ROSWELL's patents serve as a barrier of entry, preventing any BP from developing a competing dendritic-based treatment.
5. Wall-street would severely limit NWBO's ability to raise needed funding, resulting in preventing NWBO from crossing the finish line. NWBO not only got to the finish line, they may very well bankrupt money-makers and SHFs via the outcome of its lawsuit and open the floodgates for other companies to sue these bastards.
Despite all of this, you and others conclude NWBO management is incompetent. WHY?
“When bad men combine, the good must associate; else they will fall one by one, an unpitied sacrifice in a contemptible struggle.”
~Edmund Burke
Recent NWBO News
- Northwest Biotherapeutics Announces Establishment Of the Company's Own Dedicated Leukapheresis Clinic • PR Newswire (US) • 04/21/2026 01:30:00 PM
- Northwest Biotherapeutics Announces Establishment Of the Company's Own Dedicated Leukapheresis Clinic • PR Newswire (US) • 04/21/2026 01:30:00 PM
- Form EFFECT - Notice of Effectiveness • Edgar (US Regulatory) • 04/21/2026 04:15:08 AM
- Form POS AM - Post-Effective amendments for registration statement • Edgar (US Regulatory) • 04/16/2026 09:25:30 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 04/07/2026 04:30:50 PM
- Form NT 10-K - Notification of inability to timely file Form 10-K 405, 10-K, 10-KSB 405, 10-KSB, 10-KT, or 10-KT405 • Edgar (US Regulatory) • 03/31/2026 09:04:37 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/15/2026 10:06:20 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/02/2026 10:14:59 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 11/28/2025 09:43:27 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 11/25/2025 10:23:07 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/20/2025 09:26:03 PM
- Form PRE 14A - Other preliminary proxy statements • Edgar (US Regulatory) • 11/19/2025 09:15:48 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/14/2025 09:44:21 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/31/2025 04:29:10 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/30/2025 08:40:05 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/24/2025 04:28:38 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/14/2025 06:22:26 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/14/2025 09:00:38 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 07/01/2025 09:04:38 PM
